Terns Pharmaceuticals, Inc.
TERN
Classificação em ações
#3584
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Preço da ação
$52.95
Última sincronização: 2026-05-15
Valor de mercado
$4.77B
Variação (1 dia)
0.00%
Variação (1 ano)
529.61%
País
US
Negociar Terns Pharmaceuticals, Inc. (TERN)
Categoria
Healthcare
EPS de Terns Pharmaceuticals, Inc. (TERN)
EPS em December 2025 TTM: $-1.03
De acordo com os últimos relatórios financeiros e o preço das ações da Terns Pharmaceuticals, Inc., o EPS atual da empresa (TTM) é $-1.03. No final de 2023, a empresa teve um EPS de $-1.27, uma diminuição em relação a ao EPS de 2022, que foi de $-1.67.
Histórico de EPS da Terns Pharmaceuticals, Inc. de 2018 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $-1.03 | -8.04% |
| 2024 | $-1.12 | -11.81% |
| 2023 | $-1.27 | -23.95% |
| 2022 | $-1.67 | -15.66% |
| 2021 | $-1.98 | 22.98% |
| 2020 | $-1.61 | -41.24% |
| 2019 | $-2.74 | 270.27% |
| 2018 | $-0.74 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $17.32 | -1,781.55% |
US
|
|
| $-7.98 | 674.76% |
US
|
|
| $-5.29 | 413.59% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,793.20% |
NL
|
